Vividion is a biotechnology company focused on developing innovative therapeutics that treat major unmet clinical needs using the first platform for proteome-wide drug and target discovery. Making accessible the broad set of proteins expressed in human cells, the company’s cutting-edge platform was spun out of the labs of Vividion’s scientific founders, a team of experts in chemical biology and synthetic chemistry from The Scripps Research Institute in La Jolla, CA. Vividion is committed to advancing and applying its pioneering synthetic and proteomic chemistry platforms to create therapeutics that will make a transformative difference in patients.
Vividion Therapeutics total Funding
Vividion Therapeutics latest funding size
Time since last funding
|2 years ago|
Vividion Therapeutics investors
|Versant Ventures, Cardinal Partners, ARCH Venture Partners, Altitude Life Science Ventures, Celgene, Casdin Capital, Biotechnology Value Fund, Nextech Invest, Trinitas Capital, Mubadala Ventures, Mirae Asset Global Investments|
When was Vividion Therapeutics founded?
Vividion Therapeutics was founded in 2013.
Who are Vividion Therapeutics key executives?
Vividion Therapeutics's key executives are Bob Abraham, Jeff Hatfield and Robert Abraham.
Who are Vividion Therapeutics competitors?
Competitors of Vividion Therapeutics include Plasma Industries, Serum Institute of India and Bio Farma.
Receive alerts for 300+ data fields across thousands of companies